{"id":"shr-1819","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL6068589","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SHR-1819 works by binding to the molecular target, which leads to a specific biological response. This response is thought to be beneficial for the treatment of certain conditions.","oneSentence":"SHR-1819 is a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:27.602Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown"}]},"trialDetails":[{"nctId":"NCT06012812","phase":"PHASE2","title":"A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2023-09-06","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":79},{"nctId":"NCT07321951","phase":"PHASE2","title":"A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2026-01-09","conditions":"Moderate-to-severe Atopic Dermatitis","enrollment":200},{"nctId":"NCT07309055","phase":"PHASE3","title":"A Phase III Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-12","conditions":"Adolescents With Moderate-to-severe Atopic Dermatitis","enrollment":201},{"nctId":"NCT07264335","phase":"PHASE1","title":"A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-12","conditions":"Atopic Dermatitis","enrollment":160},{"nctId":"NCT06468956","phase":"PHASE3","title":"Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2024-06-14","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":652},{"nctId":"NCT07091357","phase":"PHASE2","title":"A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2025-08-06","conditions":"Seasonal Allergic Rhinitis","enrollment":100},{"nctId":"NCT06713499","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2024-12-18","conditions":"Children and Adolescents With Moderate-to-severe Atopic Dermatitis","enrollment":50},{"nctId":"NCT06554509","phase":"PHASE2, PHASE3","title":"Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2024-09-19","conditions":"Prurigo Nodularis","enrollment":236},{"nctId":"NCT05549947","phase":"PHASE2","title":"Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2022-10-08","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":158},{"nctId":"NCT04772365","phase":"PHASE1","title":"A Phase 1, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Escalation Study in Healthy Subjects","status":"COMPLETED","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2021-03-01","conditions":"Asthma","enrollment":52},{"nctId":"NCT04561128","phase":"PHASE1","title":"A Trial of SHR-1819 in Healthy Subjects","status":"COMPLETED","sponsor":"Atridia Pty Ltd.","startDate":"2020-11-01","conditions":"Healthy Volunteers","enrollment":42},{"nctId":"NCT05197023","phase":"PHASE1","title":"A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS","status":"UNKNOWN","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2022-01","conditions":"Moderate to Severe Atopic Dermatitis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-1819","genericName":"SHR-1819","companyName":"Guangdong Hengrui Pharmaceutical Co., Ltd","companyId":"guangdong-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1819 is a small molecule drug that targets the molecular target. Used for Unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}